Navigation Links
University of Maryland School of Medicine researchers find potential novel treatment for influenza
Date:5/1/2013

An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1. The scientists found that a drug called Eritoran can protect mice from death after they have been infected with a lethal dose of influenza virus. The potential value of this drug as single therapy or in combination with antivirals is further supported by previous research that found that it is safe for use in humans. The findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.

Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4). Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality. In their new study, they extend these findings by showing that Eritoran a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus. Existing antiviral medications must be administered within two days of infection to be optimally effective.

Annual influenza epidemics are estimated to result in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths yearly worldwide. The virus is continually evolving and new variants give rise to seasonal outbreaks. Increasing resistance to existing antiviral therapies and the short time-frame in which thes
'/>"/>

Contact: Karen Robinson
krobinson@som.umaryland.edu
410-706-7590
University of Maryland Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. University of Houston study shows BP oil spill hurt marshes, but recovery possible
2. University of Alberta led research may have discovered how memories are encoded in our brains
3. BGI, University of Helsinki and Wuhan University sign a MOU concerning cooperation on genomics
4. Marshall University study may lead to new treatments for prostate cancer
5. University leads £6 million EU project to tackle obesity
6. A University of Tennessee professors hypothesis may be game changer for evolutionary theory
7. Life expectancy may affect when you get married, divorced, have kids: Queens University study
8. University of Toronto biologists predict extinction for organisms with poor quality genes
9. University of Minnesota invention helps advance reliability of alternative energy
10. Israel names Tel Aviv Universitys Renewable Energy Center a Center of Research Excellence
11. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... will study the unique bioelectric signaling system of the ... health. The OU researcher is working to understand ... the signals used to map the world around them. ... of 500-600 discharges a second throughout their lives. ... extreme, but necessary for survival. , "There is evidence ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... Indians of Panama, an international team of scientists ... part, responsible, for the heart-healthy benefits of certain ... who are from the University of California, Davis; ... Medical School, hope the findings will lead to ...
... "fingerprinting" techniques, two University of Minnesota researchers have become ... plants with genetic markers. , Hemp, a crop ... the most abundant illegal drug of abuse in the ... They differ in levels of the psychoactive drug tetrahydrocannabinol ...
... used for genetics-versus-environment studies has joined the panoply of ... genomes have been sequenced. , At the Daphnia Genomics ... and Joint Genome Institute scientists announced they've completed a ... as it's better known to high school biology students. ...
Cached Biology News:Heart-healthy compound in chocolate identified 2New DNA 'fingerprinting' technique separates hemp from marijuana 2Genome sequencing is for ecologists, too 2
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
(Date:9/21/2014)... For the first time, scientists have discovered how to ... strength and stiffness greater than that of today,s strongest ... a research team led by John V. Badding, a ... published in the 21 September 2014 issue of the ... point of view, our discovery is intriguing because the ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
... FRANCISCO, Calif., Oct. 25 Cell,Genesys, Inc. (Nasdaq: ... and chief executive officer, and Sharon E. Tetlow, senior,vice ... host a,conference call relating to the company,s third quarter ... on Thursday, November 1,2007, at 2:00 p.m. PT/ 5:00 ...
... will Include World-Renowned RNase and RNA Researchers, ... mechanics of ribonuclease (RNase) therapeutics will be the ... hosted by Alfacell,Corporation (Nasdaq: ACEL ). ... chief,executive officer, and David Sidransky, M.D., Alfacell,s scientific,advisory ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
...
Candida (IgG) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
Biology Products: